MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-09-2023
NeuBase Therapeutics Operating Expenses 2011-2026 | NBSE
Annual Operating Expenses NeuBase Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 33.3 M | 26.6 M | 17.1 M | 26.3 M | 9.08 M | 23.9 M | 25.3 M | 17.5 M | 9.12 M | 4.62 M | 3.29 M | 1.24 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 33.3 M | 1.24 M | 16.4 M |
Quarterly Operating Expenses NeuBase Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.81 M | 3.69 M | 4.16 M | 4.6 M | 7.72 M | 8.36 M | 9.93 M | 7.3 M | 19.4 M | 8.84 M | 5.9 M | 4.66 M | 12 M | 3.82 M | 4.66 M | 3.78 M | 5.38 M | 1.96 M | 3.78 M | 1.47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.92 M | - | 2.06 M | 1.97 M | 2.02 M | 2.82 M | 1.34 M | 2.02 M | 815 K | 2.04 M | 635 K | 815 K | 497 K | 868 K | 302 K | 497 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 19.4 M | 302 K | 4.19 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
292 M | $ 3.53 | -0.98 % | $ 1.05 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
AC Immune SA
ACIU
|
79.7 M | $ 3.21 | 2.56 % | $ 229 M |  Schweiz |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
65.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 0.79 | 0.01 % | $ 4.31 M | China |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
ADC Therapeutics SA
ADCT
|
334 M | $ 4.12 | -1.9 % | $ 105 M | Schweiz |
 |
Arcturus Therapeutics Holdings
ARCT
|
158 M | $ 6.59 | -0.6 % | $ 180 M |  Israel |
 |
argenx SE
ARGX
|
2.27 B | $ 709.76 | 0.92 % | $ 25 B |  Niderland |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.41 | -5.54 % | $ 8.2 B |  Australia |
 |
Ascendis Pharma A/S
ASND
|
338 M | $ 229.9 | -0.49 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
181 M | $ 6.08 | 0.5 % | $ 495 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
BioCardia
BCDA
|
15.7 M | $ 1.28 | 0.55 % | $ 27.1 M | USA |
 |
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Anika Therapeutics
ANIK
|
51.6 M | $ 14.49 | 0.91 % | $ 212 M | USA |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aptose Biosciences
APTO
|
26.3 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AVEO Pharmaceuticals
AVEO
|
44.9 M | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
53.7 M | $ 2.64 | - | $ 16.6 M | USA |
 |
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.51 | - | $ 385 M | Britain |
 |
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 92.27 | 1.91 % | $ 27.2 B | Germany |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Burford Capital Limited
BUR
|
106 M | $ 8.27 | 2.61 % | $ 1.34 B | Britain |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | Britain |
 |
Actinium Pharmaceuticals
ATNM
|
42.1 M | $ 1.16 | 4.5 % | $ 34.9 M | USA |